# Align Technology Inc: financial statements, quarterly

ALGN · Nasdaq · CIK 1097149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/algn.md) · [Financials](/companies/algn/financials.md) · [Filings](/companies/algn/filings.md) · [Insiders](/companies/algn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/algn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [960](/filings/0001097149-24-000060.md) | [957 d](/filings/0001097149-26-000014.md) | [997](/filings/0001097149-25-000034.md) | [1,028](/filings/0001097149-25-000064.md) | [978](/filings/0001097149-25-000079.md) | [995 d](/filings/0001097149-26-000014.md) | [979](/filings/0001097149-26-000040.md) | [1,012](/filings/0001097149-26-000060.md) | [996](/filings/0001097149-25-000079.md) | [1,048 d](/filings/0001097149-26-000014.md) | [1,040](/filings/0001097149-26-000040.md) | [1,056](/filings/0001097149-26-000060.md) |
| Cost of revenue | $m | [297](/filings/0001097149-24-000060.md) | [287 d](/filings/0001097149-26-000014.md) | [300](/filings/0001097149-25-000034.md) | [306](/filings/0001097149-25-000064.md) | [296](/filings/0001097149-25-000079.md) | [298 d](/filings/0001097149-26-000014.md) | [299](/filings/0001097149-26-000040.md) | [304](/filings/0001097149-26-000060.md) | [356](/filings/0001097149-25-000079.md) | [364 d](/filings/0001097149-26-000014.md) | [304](/filings/0001097149-26-000040.md) | [299](/filings/0001097149-26-000060.md) |
| Gross profit | $m | [663](/filings/0001097149-24-000060.md) | [670 d](/filings/0001097149-26-000014.md) | [698](/filings/0001097149-25-000034.md) | [723](/filings/0001097149-25-000064.md) | [682](/filings/0001097149-25-000079.md) | [697 d](/filings/0001097149-26-000014.md) | [680](/filings/0001097149-26-000040.md) | [708](/filings/0001097149-26-000060.md) | [639](/filings/0001097149-25-000079.md) | [684 d](/filings/0001097149-26-000014.md) | [737](/filings/0001097149-26-000040.md) | [757](/filings/0001097149-26-000060.md) |
| Research and development | $m | [88.7](/filings/0001097149-24-000060.md) | [82.2 d](/filings/0001097149-26-000014.md) | [91.9](/filings/0001097149-25-000034.md) | [92.2](/filings/0001097149-25-000064.md) | [85.3](/filings/0001097149-25-000079.md) | [94.9 d](/filings/0001097149-26-000014.md) | [97.2](/filings/0001097149-26-000040.md) | [96.4](/filings/0001097149-26-000060.md) | [93.3](/filings/0001097149-25-000079.md) | [83.0 d](/filings/0001097149-26-000014.md) | [98.7](/filings/0001097149-26-000040.md) | [102](/filings/0001097149-26-000060.md) |
| Selling, general and administrative | $m | [408](/filings/0001097149-24-000060.md) | [403 d](/filings/0001097149-26-000014.md) | [452](/filings/0001097149-25-000034.md) | [452](/filings/0001097149-25-000064.md) | [434](/filings/0001097149-25-000079.md) | [425 d](/filings/0001097149-26-000014.md) | [448](/filings/0001097149-26-000040.md) | [449](/filings/0001097149-26-000060.md) | [418](/filings/0001097149-25-000079.md) | [442 d](/filings/0001097149-26-000014.md) | [465](/filings/0001097149-26-000040.md) | [463](/filings/0001097149-26-000060.md) |
| Operating income | $m | [166](/filings/0001097149-24-000060.md) | [172 d](/filings/0001097149-26-000014.md) | [154](/filings/0001097149-25-000034.md) | [147](/filings/0001097149-25-000064.md) | [162](/filings/0001097149-25-000079.md) | [144 d](/filings/0001097149-26-000014.md) | [131](/filings/0001097149-26-000040.md) | [163](/filings/0001097149-26-000060.md) | [96.3](/filings/0001097149-25-000079.md) | [155 d](/filings/0001097149-26-000014.md) | [142](/filings/0001097149-26-000040.md) | [154](/filings/0001097149-26-000060.md) |
| Income tax | $m | [40.7](/filings/0001097149-24-000060.md) | [48.9 d](/filings/0001097149-26-000014.md) | [53.4](/filings/0001097149-25-000034.md) | [47.3](/filings/0001097149-25-000064.md) | [50.0](/filings/0001097149-25-000079.md) | [37.0 d](/filings/0001097149-26-000014.md) | [47.2](/filings/0001097149-26-000040.md) | [48.9](/filings/0001097149-26-000060.md) | [38.0](/filings/0001097149-25-000079.md) | [40.8 d](/filings/0001097149-26-000014.md) | [36.1](/filings/0001097149-26-000040.md) | [40.4](/filings/0001097149-26-000060.md) |
| Net income | $m | [121](/filings/0001097149-24-000060.md) | [124 d](/filings/0001097149-26-000014.md) | [105](/filings/0001097149-25-000034.md) | [96.6](/filings/0001097149-25-000064.md) | [116](/filings/0001097149-25-000079.md) | [104 d](/filings/0001097149-26-000014.md) | [93.2](/filings/0001097149-26-000040.md) | [125](/filings/0001097149-26-000060.md) | [56.8](/filings/0001097149-25-000079.md) | [136 d](/filings/0001097149-26-000014.md) | [113](/filings/0001097149-26-000040.md) | [108](/filings/0001097149-26-000060.md) |
| Diluted EPS | $ per share | [1.58](/filings/0001097149-24-000060.md) | not reported | [1.39](/filings/0001097149-25-000034.md) | [1.28](/filings/0001097149-25-000064.md) | [1.55](/filings/0001097149-25-000079.md) | not reported | [1.27](/filings/0001097149-26-000040.md) | [1.72](/filings/0001097149-26-000060.md) | [0.78](/filings/0001097149-25-000079.md) | not reported | [1.57](/filings/0001097149-26-000040.md) | [1.51](/filings/0001097149-26-000060.md) |
| Basic EPS | $ per share | [1.59](/filings/0001097149-24-000060.md) | not reported | [1.40](/filings/0001097149-25-000034.md) | [1.28](/filings/0001097149-25-000064.md) | [1.55](/filings/0001097149-25-000079.md) | not reported | [1.27](/filings/0001097149-26-000040.md) | [1.72](/filings/0001097149-26-000060.md) | [0.78](/filings/0001097149-25-000079.md) | not reported | [1.58](/filings/0001097149-26-000040.md) | [1.51](/filings/0001097149-26-000060.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,239](/filings/0001097149-23-000082.md) | [937](/filings/0001097149-25-000012.md) | [866](/filings/0001097149-24-000033.md) | [761](/filings/0001097149-24-000049.md) | [1,042](/filings/0001097149-24-000060.md) | [1,044](/filings/0001097149-26-000014.md) | [873](/filings/0001097149-25-000034.md) | [901](/filings/0001097149-25-000064.md) | [1,005](/filings/0001097149-25-000079.md) | [1,095](/filings/0001097149-26-000060.md) | [1,060](/filings/0001097149-26-000040.md) | [1,103](/filings/0001097149-26-000060.md) |
| Current assets | $m | [2,702](/filings/0001097149-23-000082.md) | [2,447](/filings/0001097149-25-000012.md) | [2,479](/filings/0001097149-24-000033.md) | [2,412](/filings/0001097149-24-000049.md) | [2,597](/filings/0001097149-24-000060.md) | [2,492](/filings/0001097149-26-000014.md) | [2,402](/filings/0001097149-25-000034.md) | [2,448](/filings/0001097149-25-000064.md) | [2,534](/filings/0001097149-25-000079.md) | [2,617](/filings/0001097149-26-000060.md) | [2,655](/filings/0001097149-26-000040.md) | [2,663](/filings/0001097149-26-000060.md) |
| Total assets | $m | [6,319](/filings/0001097149-23-000082.md) | [6,084](/filings/0001097149-25-000012.md) | [6,156](/filings/0001097149-24-000033.md) | [6,158](/filings/0001097149-24-000049.md) | [6,366](/filings/0001097149-24-000060.md) | [6,215](/filings/0001097149-26-000014.md) | [6,103](/filings/0001097149-25-000034.md) | [6,219](/filings/0001097149-25-000064.md) | [6,234](/filings/0001097149-25-000079.md) | [6,234](/filings/0001097149-26-000060.md) | [6,314](/filings/0001097149-26-000040.md) | [6,418](/filings/0001097149-26-000060.md) |
| Current liabilities | $m | [2,123](/filings/0001097149-23-000082.md) | [2,067](/filings/0001097149-25-000012.md) | [2,023](/filings/0001097149-24-000033.md) | [2,040](/filings/0001097149-24-000049.md) | [2,064](/filings/0001097149-24-000060.md) | [2,038](/filings/0001097149-26-000014.md) | [1,991](/filings/0001097149-25-000034.md) | [1,995](/filings/0001097149-25-000064.md) | [1,966](/filings/0001097149-25-000079.md) | [1,920](/filings/0001097149-26-000060.md) | [1,906](/filings/0001097149-26-000040.md) | [1,909](/filings/0001097149-26-000060.md) |
| Total liabilities | $m | [2,517](/filings/0001097149-23-000082.md) | [2,453](/filings/0001097149-25-000012.md) | [2,396](/filings/0001097149-24-000033.md) | [2,400](/filings/0001097149-24-000049.md) | [2,422](/filings/0001097149-24-000060.md) | [2,363](/filings/0001097149-26-000014.md) | [2,309](/filings/0001097149-25-000034.md) | [2,306](/filings/0001097149-25-000064.md) | [2,276](/filings/0001097149-25-000079.md) | [2,185](/filings/0001097149-26-000060.md) | [2,165](/filings/0001097149-26-000040.md) | [2,185](/filings/0001097149-26-000060.md) |
| Shareholders' equity | $m | [3,802](/filings/0001097149-24-000060.md) | [3,630](/filings/0001097149-26-000014.md) | [3,760](/filings/0001097149-25-000064.md) | [3,758](/filings/0001097149-25-000079.md) | [3,944](/filings/0001097149-25-000079.md) | [3,852](/filings/0001097149-26-000060.md) | [3,794](/filings/0001097149-26-000060.md) | [3,913](/filings/0001097149-26-000060.md) | [3,957](/filings/0001097149-25-000079.md) | [4,049](/filings/0001097149-26-000060.md) | [4,149](/filings/0001097149-26-000060.md) | [4,232](/filings/0001097149-26-000060.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [287 d](/filings/0001097149-24-000060.md) | [46.9 d](/filings/0001097149-26-000014.md) | [28.7](/filings/0001097149-25-000034.md) | [160 d](/filings/0001097149-25-000064.md) | [264 d](/filings/0001097149-25-000079.md) | [286 d](/filings/0001097149-26-000014.md) | [52.7](/filings/0001097149-26-000040.md) | [129 d](/filings/0001097149-26-000060.md) | [189 d](/filings/0001097149-25-000079.md) | [223 d](/filings/0001097149-26-000014.md) | [151](/filings/0001097149-26-000040.md) | [193 d](/filings/0001097149-26-000060.md) |
| Capital expenditure | $m | [21.6 d](/filings/0001097149-24-000060.md) | [33.4 d](/filings/0001097149-26-000014.md) | [9.4](/filings/0001097149-25-000034.md) | [53.5 d](/filings/0001097149-25-000064.md) | [29.8 d](/filings/0001097149-25-000079.md) | [23.0 d](/filings/0001097149-26-000014.md) | [25.3](/filings/0001097149-26-000040.md) | [21.5 d](/filings/0001097149-26-000060.md) | [19.8 d](/filings/0001097149-25-000079.md) | [35.9 d](/filings/0001097149-26-000014.md) | [30.8](/filings/0001097149-26-000040.md) | [35.7 d](/filings/0001097149-26-000060.md) |
| Share repurchases | $m | [0.0 d](/filings/0001097149-24-000060.md) | [300 d](/filings/0001097149-26-000014.md) | [0.0](/filings/0001097149-25-000034.md) | [150 d](/filings/0001097149-25-000064.md) | [0.0 d](/filings/0001097149-25-000079.md) | [203 d](/filings/0001097149-26-000014.md) | [201](/filings/0001097149-26-000040.md) | [96.0 d](/filings/0001097149-26-000060.md) | [71.6 d](/filings/0001097149-25-000079.md) | [97.2 d](/filings/0001097149-26-000014.md) | [31.2](/filings/0001097149-26-000040.md) | [66.9 d](/filings/0001097149-26-000060.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.2](/filings/0001097149-23-000082.md) | [77.1](/filings/0001097149-24-000033.md) | [76.7](/filings/0001097149-24-000049.md) | [76.8](/filings/0001097149-24-000060.md) | [75.3](/filings/0001097149-25-000034.md) | [75.2](/filings/0001097149-25-000064.md) | [74.8](/filings/0001097149-25-000079.md) | [73.6](/filings/0001097149-26-000040.md) | [72.6](/filings/0001097149-26-000060.md) | [72.4](/filings/0001097149-25-000079.md) | [71.6](/filings/0001097149-26-000040.md) | [71.5](/filings/0001097149-26-000060.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 71,039,852 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001097149-26-000060.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.